Hi Colleague,

If your company is focussed on value for patients, then you'll undoubtedly be investing in digital therapeutics.

You'll already know that this new class of treatment is poised to make huge impact, especially when it comes to areas requiring behavioural modification for better outcomes.

But now it's time for DTx to go mainstream. Are you ahead or behind the curve?

Along with our partners at S3 Connected Health, we've taken a comprehensive look at this emerging new treatment type. Download our new, free whitepaper to assess the current state of play and the best next steps for pharma executives. In particular, you will understand the various possibilities and classes, the opportunity areas and the common pitfalls to avoid.

Get it for free, right here.

Kind regards

Blair

Blair Gottscho

Head of Operations | eyeforpharma

Tel: +44 (0) 207 375 7594

E-mail   LinkedIn   Twitter

 

 

This email was sent on behalf of eyeforpharma by HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here, or send your request in writing to the address above.
Read more about our privacy policy here. You may also request a copy in writing using the address above.

To ensure you continue to receive emails from HealthEconomics.Com, please click here.